31-03-2020 Exterior of Janssen Biologics B.V. initiate. Janssen Biologics B.V. makes, acquires and markets unique biopharmaceutical drugs. To prevent a potential pandemic, Johnson & Johnson initiated a project to develop a preventive coronavirus vaccine, Covid-19, to potentially protect people from the disease. In doing so, they build on their leadership position in the development of monoclonal antibodies. Antibodies are substances that the body produces in response to bacteria, viruses or other foreign substances. Janssen Biologics' innovative products focus on three main disease categories
Image details
Contributor:
Sipa US / Alamy Stock PhotoImage ID:
2EJXRHKFile size:
44.1 MB (2.1 MB Compressed download)Releases:
Model - no | Property - noDo I need a release?Dimensions:
4604 x 3349 px | 39 x 28.4 cm | 15.3 x 11.2 inches | 300dpiDate taken:
31 March 2020Photographer:
PPEMore information:
This image could have imperfections as it’s either historical or reportage.
31-03-2020 Exterior of Janssen Biologics B.V. initiate. Janssen Biologics B.V. makes, acquires and markets unique biopharmaceutical drugs. To prevent a potential pandemic, Johnson & Johnson initiated a project to develop a preventive coronavirus vaccine, Covid-19, to potentially protect people from the disease. In doing so, they build on their leadership position in the development of monoclonal antibodies. Antibodies are substances that the body produces in response to bacteria, viruses or other foreign substances. Janssen Biologics' innovative products focus on three main disease categories: cardiovascular and immunological disorders and cancer. (Photo by PPE/Sipa USA)